Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms

Chemistry & Biology
Lisa WrightRoderick E Hubbard

Abstract

Inhibition of the ATPase activity of the chaperone protein HSP90 is a potential strategy for treatment of cancers. We have determined structures of the HSP90alpha N-terminal domain complexed with the purine-based inhibitor, PU3, and analogs with enhanced potency both in enzyme and cell-based assays. The compounds induce upregulation of HSP70 and downregulation of the known HSP90 client proteins Raf-1, CDK4, and ErbB2, confirming that the molecules inhibit cell growth by a mechanism dependent on HSP90 inhibition. We have also determined the first structure of the N-terminal domain of HSP90beta, complexed with PU3. The structures allow a detailed rationale to be developed for the observed affinity of the PU3 class of compounds for HSP90 and also provide a structural framework for design of compounds with improved binding affinity and drug-like properties.

References

Mar 1, 1991·Acta Crystallographica. Section A, Foundations of Crystallography·T A JonesM Kjeldgaard
Jul 4, 1990·Journal of the National Cancer Institute·P SkehanM R Boyd
Nov 17, 1998·The Journal of Cell Biology·W M ObermannF U Hartl
Jan 19, 2000·Trends in Biochemical Sciences·R Dutta, M Inouye
Jan 5, 2002·Expert Opinion on Biological Therapy·Alison Maloney, Paul Workman
Apr 5, 2003·Cancer Cell·Jennifer S IsaacsLen Neckers
Jan 1, 1993·Acta Crystallographica. Section D, Biological Crystallography·V S Lamzin, K S Wilson
May 1, 1997·Acta Crystallographica. Section D, Biological Crystallography·G N MurshudovE J Dodson

❮ Previous
Next ❯

Citations

Dec 13, 2006·Journal of Medicinal Chemistry·Niu HuangJohn J Irwin
Feb 21, 2008·The Journal of Biological Chemistry·Ahmed ChadliDavid O Toft
Jul 21, 2011·Protein Engineering, Design & Selection : PEDS·David J Huggins, Bruce Tidor
Oct 2, 2008·Journal of the Royal Society, Interface·Aixia YanW Graham Richards
Jul 28, 2006·Cold Spring Harbor Symposia on Quantitative Biology·P Workman
Jul 21, 2006·Acta Crystallographica. Section D, Biological Crystallography·Thomas C TerwilligerJudith D Cohn
Apr 25, 2007·Acta Crystallographica. Section D, Biological Crystallography·Thomas C TerwilligerLi Wei Hung
Jan 5, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Len Neckers, Paul Workman
Jan 29, 2011·Reproductive Biology and Endocrinology : RB&E·Eusebio S PiresVrinda V Khole
Oct 23, 2013·PLoS Neglected Tropical Diseases·Juan Carlos PizarroRaymond Hui
May 20, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Rafiqa EachkotiE PremKumar Reddy
Nov 17, 2006·Nature Chemical Biology·Ian Collins, Paul Workman
Sep 3, 2013·Nature Chemical Biology·Pallav D PatelGabriela Chiosis
Jan 31, 2006·Expert Opinion on Therapeutic Targets·Gabriela Chiosis
Oct 27, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Stefano Forli
Sep 1, 2006·Expert Opinion on Drug Discovery·Xavier Barril, Xavier Fradera
Jan 1, 2008·Expert Opinion on Drug Discovery·Gabriela ChiosisWeilin Sun
Mar 11, 2005·Expert Opinion on Emerging Drugs·Len Neckers, Katharine Neckers
Aug 8, 2009·Computational Biology and Chemistry·Antonino LauriaAnna Maria Almerico
Nov 10, 2015·Journal of Molecular Graphics & Modelling·Salla I VirtanenOlli T Pentikäinen
Apr 3, 2009·Trends in Biotechnology·Rob L M van Montfort, Paul Workman
Jan 31, 2009·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Yanyan LiDuxin Sun
Dec 17, 2008·Journal of Molecular Graphics & Modelling·Antonino LauriaAnna Maria Almerico
Sep 4, 2007·Journal of Molecular Biology·Jonathan J PhillipsSophie E Jackson
May 22, 2007·Annals of the New York Academy of Sciences·Paul WorkmanNeal Rosen
Oct 12, 2004·Drug Discovery Today·Gabriela ChiosisDavid Solit
Mar 17, 2006·The International Journal of Biochemistry & Cell Biology·Antal OroszAndras Perczel
Feb 8, 2006·Analytical Biochemistry·R HowesM J Drysdale
May 25, 2015·Journal of Molecular Biology·Kristoffer R Brandvold, Richard I Morimoto
Jun 29, 2015·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Matthew Trendowski
Mar 22, 2015·Glycobiology·Cristina Y ZamoraKrishna Kumar
Dec 17, 2014·Bioinformatics·Benoist LaurentMarc Baaden
Apr 26, 2016·Accounts of Chemical Research·Antonia StankRebecca C Wade
Jun 23, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yong LiShu-Fan Yin
Aug 4, 2016·Bioorganic & Medicinal Chemistry·Antonia S J S MeyJulien Michel
Oct 26, 2016·Journal of Computer-aided Molecular Design·Diogo Santos-Martins

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.